«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年06期

页码:

501-504512

栏目:

基础医学

出版日期:

2018-11-20

文章信息/Info

Title:

Identification of keygenes and pathwaysoftamoxifen-resistancein breast cancer

作者:

柴慈曼; 杨绍时

（天津医科大学第二医院甲状腺乳腺外科，天津300211）

Author(s):

CHAI Ci-man;  YANG Shao-shi

（Department of Thyroid and Breast Surgery ,The Second Hospital, Tianjin Medical University, Tianjin 300211, China）

关键词:

他莫昔芬耐药; 乳腺癌; 生物信息学

Keywords:

tamoxifenresistance; breast neoplasms; bioinformatics

分类号:

R737.9

DOI:

-

文献标志码:

A

摘要:

目的：利用美国国家生物技术信息中心基因表达数据库中雌激素受体阳性乳腺癌表达谱芯片进行生物信息学分析，筛选他莫昔芬耐药的关键基因和信号通路。方法：利用基因芯片GSE26459，R软件分析得到差异基因，DAVID 进行Gene Ontology和KEGG富集分析，STRING绘制蛋白作用网络。GSEA富集分析得到耐药相关通路及基因。结合蛋白作用网络筛选目标基因并验证。结果：筛选出差异基因1 516个，上调基因505个，下调基因624个。通路富集分析发现脂肪酸代谢通路、细胞粘附、胰岛素抵抗等信号通路在乳腺癌的他莫昔芬耐药中起重要作用，并在富集通路中筛选出ACSL1等候选目标基因并验证。结论：利用生物信息学有效分析他莫昔芬耐药的基因芯片数据，为他莫昔芬耐药的治疗靶点提供重要依据。

Abstract:

Objective: To screen and explore the candidate genes and the molecular signaling pathwaysoftamoxifen resistance in ER-positive breast cancerbased on the Gene Expression Omnibus （GEO）. Methods: Differentially expressed genes (DEGs) were identified in tamoxifen-sensitive samples and were compared with tamoxifen-resistance samples based on the microarray GSE26459usingthe R software,and then were subjected togene ontology enrichment analysisand pathway enrichment analysis by DAVID database. In addition, we analyzed the protein protein interaction（PPI） network of DEGs with Search Tool for the Retrieval of Interacting Genes (STRING) database. Western-blot verified the expression of the candidate gene. Results: There were 1 516 DEGs between in tamoxifen-sensitive and resistance breast cancer, which contained 505up-regulated and 624 down-regulated genes. GO categories andKEGG analysis showed DEGs were mainly enriched inFatty acid metabolism,cell adhesion, and insulin resistance pathways. ACSL1 might be the key gene in the enriched pathways. Conclusion: The study may provide some basis of for treatment of tamoxifen-resistance breast cancerby bioinformatics analysis.

参考文献/References:

[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115
[2] Turner N C, Neven P, Loibl S, et al.Advances in the treatment of advanced oestrogen-receptor-positive breast cancer[J]. Lancet,2017, 389(187):2403
[3] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: Atlas, a randomisedtrial[J]. Lancet,2013,381(9869):805
[4] Zhang Y J, Leonard M, Shu Y, et al. Overcoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional pRNAnanoparticles[J].ACS Nano, 2017, 11(1):335
[5] Johnston S R. Enhancing endocrine therapy for hormone Receptor-Positive advanced breast cancer: cotargeting signaling pathways[J].J Natl Cancer Inst,2015, 107(10):djv212
[6] Neuhouser M L, Aragaki A K, Prentice R L, et al. Overweight, Obesity,and Postmenopausal Invasive Breast Cancer RiskA Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials[J]. JAMA Oncol, 2015，1(5):611
[7] Rose D P, Komninou D, Stephenson G O.Obesity, adipocytokines,and insulin resistance in breast cancer[J].Obes Rev,2004,5(3):153
[8] Yen M C, Kan J Y, Hsieh C J, et al. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance[J]. Oncol Rep,2017, 37(6):3253
[9] Huang J F, Duran A, Reina-Campos M A, et al. Adipocyte p62/SQSTM1 suppresses tumorigenesis through opposite regulations of metabolism in adipose tissue and tumor[J]. Cancer Cell, 2018, 33(4):770
[10] Steelman L S, Martelli A M, Cocco L, et al. The therapeutic potential of mTOR inhibitors in breast cancer[J]. Br JClinPharmacol,2016, 82(5):1189
[11] Porta R, Blancafort A, Casoliva G, et al. Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients[J]. Menopause,2014,21(2):188
[12] Yang Y J, Kim K M, An J H, et al. Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients[J]. Breast, 2016, 28(4):67
[13] Bao J S, Zhu L P, Zhu Q, et al. SREBP-1 is an Independent prognostic marker and promotes invasion and migration in breast cancer[J].OncolLett, 2016, 12(4):2409
[14] Liu W, Furuta E, Shindo K, et al. Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway[J]. Breast Cancer Res Treat, 2011, 128(1):57
[15] Bullock M. FOXO factors and breast cancer: outfoxing endocrine resistance[J]. EndocrRelat Cancer, 2016, 23(2):R113
[16] Lewis-Wambi J S, Jordan V C. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit[J]. Breast Cancer Research,2009, 11(3):206
[17] Guest S K, Ribas R, Pancholi S, et al. Src is a potential therapeutic target in Endocrine-Resistant breast cancer exhibiting low estrogen Receptor-Mediated transactivation[J]. PLoS One, 2016, 11(6):e0157397

相似文献/References:

[1]朱悦,张诗武,张丹芳,等.TA2小鼠自发乳腺癌血清蛋白质组学研究[J].天津医科大学学报,2013,19(05):373.
[2]刘 营,孙保存,刘铁菊,等.AURKA蛋白激酶在三阴乳腺癌干细胞形成血管拟态中的实验研究[J].天津医科大学学报,2013,19(06):437.
　LIU Ying,SUN Bao-cun,LIU Tie-ju,et al.Experimental study of AURKA protein kinase in the formation of vascular mimicry in triple-negative breast cancer stem cells[J].Journal of Tianjin Medical University,2013,19(06):437.
[3]伦淑敏.HOXA5基因真核表达质粒的构建及在乳腺癌细胞中的功能研究[J].天津医科大学学报,2014,20(05):337.
　LUN Shu-min. Construction of HOXA5 eukaryotic expression plasmid of and its biological significance in breast cancer cells[J].Journal of Tianjin Medical University,2014,20(06):337.
[4]伦淑敏.肌细胞增强因子2A基因真核表达质粒的构建及对乳腺癌细胞MCF-7增殖能力的影响[J].天津医科大学学报,2014,20(06):429.
　LUN Shu-min.Construction of myocyte enhancer factor 2A eukaryotic expression plasmid and effects on cell proliferation in breast cancer cell line MCF7[J].Journal of Tianjin Medical University,2014,20(06):429.
[5]孙秀梅,张 飞,田 然,等.Nanog表达上调促进乳腺癌细胞MCF-7的增殖和侵袭[J].天津医科大学学报,2014,20(06):421.
　SUN Xiu-mei,ZHANG Fei,TIAN Ran,et al.Up-regulation of Nanog promotes cell proliferation and invasion in breast cancer cells MCF-7[J].Journal of Tianjin Medical University,2014,20(06):421.
[6]张 洁,张 飞,冀 为,等. SHP2不同突变体对乳腺癌细胞的迁移和侵袭能力的影响[J].天津医科大学学报,2015,21(02):93.
　ZHANG Jie,ZHANG Fei,JI Wei,et al. Effect of different SHP2 mutants on breast cancer cell migration and invasion[J].Journal of Tianjin Medical University,2015,21(06):93.
[7]蔡 隽. FOXQ1稳定表达乳腺癌细胞系的建立及鉴定[J].天津医科大学学报,2015,21(04):292.
　CAI Jun.Establishment and identification of cell lines with stable expression of FOXQ1 in MDA-MB-231-luc[J].Journal of Tianjin Medical University,2015,21(06):292.
[8]蔡 隽 综述,冯玉梅 审校.叉头框转录因子调控乳腺癌生物学特性的研究进展[J].天津医科大学学报,2015,21(05):455.
[9]任宗娜.沉默Notch4基因对乳腺癌细胞系MDA-MB-231增殖和迁移侵袭能力的影响[J].天津医科大学学报,2015,21(06):469.
　REN Zong-na.Inhibition effect of?silencing?? Notch4 gene on the proliferation and migration and invasion activity of? breast cancer cell line?MDA-MB-231[J].Journal of Tianjin Medical University,2015,21(06):469.
[10]周岩,宋伟杰,张飞,等.人附睾蛋白4在乳腺癌发生发展中的机制研究[J].天津医科大学学报,2015,21(06):466.
　ZHOU Yan,SONG Wei-jie,ZHANG Fei,et al.Mechanism of human epididymis protein 4 in development and progression of breast cancer[J].Journal of Tianjin Medical University,2015,21(06):466.
[11]王世霞,杨艳芳,马 宁,等.基于芯片数据的雌激素受体阳性乳腺癌他莫昔芬耐药相关基因分析[J].天津医科大学学报,2019,25(01):32.
　WANG Shi-xia,YANG Yan-fang,MA Ning,et al.Bioinformatics analysis of key genes for tamoxifen resistancein estrogen receptor positive breast cancer[J].Journal of Tianjin Medical University,2019,25(06):32.

备注/Memo

备注/Memo:

基金项目 天津医科大学第二医院青年基金项目资助（2017ydey05）
作者简介 柴慈曼（1985-），女，医师，博士在读，研究方向：乳腺癌内分泌耐药机制； 通信作者：杨绍时， E-mail ： chaiciman@vip.sina.com。

常用功能

更新日期/Last Update: 2018-11-30